Comparative Pharmacology
Head-to-head clinical analysis: FOUNDAYO versus LORYNA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOUNDAYO versus LORYNA.
FOUNDAYO vs LORYNA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective progesterone receptor modulator with mixed agonist/antagonist activity on progesterone receptors, primarily antagonistic in the uterus leading to inhibition of endometrial proliferation.
Selective mineralocorticoid receptor antagonist, blocking aldosterone binding to the mineralocorticoid receptor in epithelial and nonepithelial tissues.
100 mg orally once daily
5 mg orally once daily, with or without food. Maximum dose 10 mg once daily.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in healthy adults; prolonged to 6-8 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 12 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 18–24 hours in healthy adults; may be prolonged in severe hepatic impairment.
Primarily renal (80-90% as unchanged drug), with 10-20% fecal via biliary excretion. Less than 5% metabolized.
Primarily excreted via feces (80%) after biliary elimination; renal excretion accounts for approximately 10% as unchanged drug and metabolites.
Category C
Category C
Oral contraceptive
Oral contraceptive